STUDY SEARCH RESULTS

1 study found for your search request:  1026-003

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants with Hematologic Malignancies (MK-102...
Condition: Hematologic Malignancies, Waldenstroms macroglobulinaemia, Non-Hodgkins lymphoma, Chronic lymphocytic leukaemia
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT04728893
Status: Recruiting
Has Enrolling Locations in US or Canada




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site